Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: RP-6306|DRUG: Gemcitabine|OTHER: Observation|DRUG: Niraparib|DRUG: Fulvestrant
Sponsor: Canadian Cancer Trials Group